CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $278,000 | -69.8% | 3,826 | -53.6% | 0.03% | -66.7% |
| Q3 2021 | $922,000 | -28.8% | 8,239 | +3.0% | 0.09% | -30.8% |
| Q2 2021 | $1,295,000 | +37.3% | 8,002 | -1.8% | 0.13% | +19.3% |
| Q1 2021 | $943,000 | -8.3% | 8,145 | +32.7% | 0.11% | -12.8% |
| Q4 2020 | $1,028,000 | +68.8% | 6,138 | +4.2% | 0.12% | +13.6% |
| Q3 2020 | $609,000 | +46.4% | 5,890 | +11.1% | 0.11% | +23.6% |
| Q2 2020 | $416,000 | +49.6% | 5,300 | +2.9% | 0.09% | +34.8% |
| Q1 2020 | $278,000 | +62.6% | 5,150 | +51.5% | 0.07% | +73.7% |
| Q3 2019 | $171,000 | +31.5% | 3,400 | +28.3% | 0.04% | +26.7% |
| Q2 2019 | $130,000 | – | 2,650 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |